Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 1, 2023
-
Nov 1, 2022
-
Sep 6, 2022
-
May 23, 2022
-
Feb 17, 2022--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $56.1 Million for the Fourth Quarter and $188.5 Million for the Full Year 2021; Anticipate at Least 30% Year Over Year Annual Growth for 2022--
-
Oct 28, 2021--ARIKAYCE® (amikacin liposome inhalation suspension) Now Launched in Three Major Territories; Positive Early Trends in Japan--
-
Aug 5, 2021--ARIKAYCE® (amikacin liposome inhalation suspension) Now Launched in Japan; Available in Three Major Territories--
-
May 25, 2021
-
May 19, 2021-Retrospective analysis of patients with COPD and NTM lung disease demonstrates statistically significantly higher mortality compared to patients with COPD without NTM lung disease-
-
May 6, 2021--ARIKAYCE® (amikacin liposome inhalation suspension) Approved in Japan for Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with a Multidrug Regimen--
-
Mar 23, 2021-- First and Only Therapy Approved in Japan, Europe, and United States for This Difficult-To-Treat Condition --
-
Feb 25, 2021--ARIKAYCE EU Launch Progresses, with Product Now Available and Reimbursed in Germany and the Netherlands--
-
Feb 24, 2021
-
Feb 19, 2021--TPIP Generally Safe and Well Tolerated in Healthy Volunteers--
-
Feb 16, 2021--Call Scheduled for Friday, February 19, 2021, at 8:30 a.m. ET--
-
Jan 4, 2021--First Patient Dosed in Post-Marketing Program Intended to Support Full FDA Approval of ARIKAYCE and sNDA in Newly Diagnosed Patients--
-
Dec 2, 2020--First Patient Dosed in Global, Registrational Study of First-in-Class Treatment Candidate--
-
Nov 2, 2020
-
Oct 29, 2020--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $43.6 Million for Third Quarter 2020--
-
Oct 28, 2020-- ARIKAYCE is the First and Only Therapy Approved in Both the European Union and United States for This Difficult-To-Treat Condition --
-
Sep 30, 2020- Initiated Phase 1 study of treprostinil palmitil inhalation powder (TPIP); Phase 2a study in pulmonary arterial hypertension planned for 2021 -
-
Sep 16, 2020
-
Sep 9, 2020
-
Sep 7, 2020--New Data from WILLOW Study also Presented During Late-Breaking Session at European Respiratory Society International Congress--
-
Aug 6, 2020--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $42.5 Million for Second Quarter 2020--
